Geron (GERN) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of Rytelo for the treatment of adult patients with transfusion-dependent anemia due to lower risk myelodysplastic syndromes.
The company said the committee considered the data from a phase 3 clinical trial, where Rytelo reduced patients' need for red blood cell transfusions in the first 24 weeks of treatment, compared with placebo.
Geron said the European Commission is set to review the committee's recommendation and is expected to issue its final decision on the marketing authorization application in the coming months.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。